• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 5, 2018

View Archived Issues

ASCO puzzler: Nektar nicked on early data despite phase III plans

CHICAGO – In a gigantic cancer meeting yielding few surprises, even the tiniest roil can send a biopharma into stormy seas. For Nektar Therapeutics Inc., the American Society of Clinical Oncology (ASCO) became the perfect storm for that scenario. Read More

Chemo regimen toppling Gemzar in pancreatic as surgery timing explored

CHICAGO – The last full day of the American Society of Clinical Oncology (ASCO) annual meeting included hopeful data regarding pancreatic tumors, long known as one of the more aggressive and intractable types. One dataset showed chemotherapy beat standard-of-care (SOC) Gemzar (gemcitabine, Eli Lilly and Co.), which has been favored for 10 years, and the other demonstrated that patients given chemo with radiotherapy before surgery conferred better disease-free survival than starting therapy with resection, the current SOC. Read More

Taselisib goes off target, disappoints in advanced breast cancer

CHICAGO – Taselisib (GDC-0032, RG-7604), the beta-isoform sparing phosphoinositide 3-kinase (PI3K) inhibitor previously advanced to no avail in non-small-cell lung cancer by Roche Holding AG unit Genentech Inc., showed only modest benefit in the phase III SANDPIPER study in individuals with estrogen receptor (ER)-positive, PIK3CA-mutant locally advanced (LA) or metastatic breast cancer (MBC). Read More

DoD's medical, biodefense leaders encourage more private sector engagement

BOSTON – Following the Senate Health, Education, Labor and Pensions Committee's overwhelming approval to reauthorize the Pandemic and All Hazards Preparedness Act, which is set to expire in September, the House starts to examine renewal options for health emergency preparedness programs this week. It helps fund U.S. response to future threats and beef up the nation's medical countermeasure enterprise. But ultimately, some of the projects its funds flow to also support civilian biopharma ventures. Read More

When 'hairy' met 'moxe': Phase III dataset lends weight to BLA filing

CHICAGO – With a phase III success for moxetumomab pasudotox (moxe, formerly CAT-8015 or HA22) in the bag, Astrazeneca plc and its Medimmune unit aim to have the first drug approval in more than two decades to treat hairy cell leukemia (HCL). Read More

Trophos-discovered SMA drug dropped by Roche

LONDON – Roche Holding AG has pulled the plug on its spinal muscular atrophy (SMA) drug, olesoxime (RG-6083), just as it was expected to start a phase III trial, blaming among other difficulties the higher hurdle set by Biogen Inc.'s Spinraza (nusinersen), for how effective a new treatment needs to be. Read More

Step aside, chemo: Merck NSCLC Keytruda outcome marks 'extraordinary' era

CHICAGO – Speaking at the American Society of Clinical Oncology meeting, John Heymach of Houston's MD Anderson Cancer Center, called new phase III data with Merck & Co. Inc.'s Keytruda (pembrolizumab) "a double whammy" of upside for advanced non-small-cell lung cancer (NSCLC) patients: non-chemotherapy benefit with lower side effects. "An era in which chemotherapy was the only option for NSCLC patients has drawn to a close," he said. Read More

HHS: Implementing 340B rule now would be counterproductive, disruptive

Despite opposition, the U.S. Department of Health and Human Services (HHS) is going ahead with its plan to delay implementing a 340B rule for another year. Read More

Molecular profiling at next-gen sequencing scale looks for big 'IMPACT' in PM

CHICAGO – Is precision medicine (PM) finally within sight? The long-heralded but largely overhyped model got a shot in the arm at the American Society of Clinical Oncology (ASCO) annual meeting in a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large personalized medicine trial. Investigators found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types. Read More

PC care's racial disparities can be fixed, but may take intervention by regulators

CHICAGO – The word "race," when used in drug development, usually suggests a contest to reach the market first, but at the American Society of Clinical Oncology (ASCO) meeting, it became key topic of talk – more than once – in prostate cancer (PC) trials. Read More

Pulling tumors' Lynch-pin, MSI-H test locates broader threat to compel screening

CHICAGO – Research unveiled at the American Society of Clinical Oncology (ASCO) meeting equals what one specialist called "an absolutely practice-changing study" related to high microsatellite instability (MSI-H), a genomic marker associated with genetic mutations in tumors, and its relation to Lynch syndrome (LS), an autosomal dominant inherited condition known to increase the risk of developing some cancers. Read More

Take it or leave it? Sutent meant to foment dissent, surgery question rethink

CHICAGO – Data from a randomized phase III trial showing that many people with renal cell carcinoma (RCC) can avoid surgery to remove the kidney "flipped the existing paradigm," said Sumanta Pal, medical oncologist with Duarte, Calif.-based City of Hope. "Even in the context of patients with advanced disease that has spread to the lungs, liver and other sites [cases account for about 20 percent of all worldwide], we've been removing the kidney, but admittedly this isn't based on a very high level of evidence until now," he said. Read More

Lung shots show promise; Tecentriq, new blood test could work but ... Merck

CHICAGO – Phase III Impower131 findings with Tecentriq (atezolizumab, Roche Holding AG) when combined with chemotherapy in squamous-cell lung cancer, along with separate discoveries related to a would-be new blood test for early stage lung cancer emerged at the American Society of Clinical Oncology (ASCO) meeting. Read More

Old made new in young: Low-dose chemo betters rare RMS cancer for kids

CHICAGO – "It's remarkable to me how the pediatric oncology community manages to continue to make great strides by using old drugs in new ways," American Society of Oncology (ASCO) Chief Medical Officer Richard Schilsky said during the group's meeting, as he spoke about the first advance in 30 years in rhabdomyosarcoma (RMS), a rare cancer of the muscle tissue that strikes children. Read More

Geriatric oncology means more than drugs, and GA could improve outcomes

CHICAGO – Rushed oncologists may feel they don't have time to talk through the concerns of older patients with them, and a systematic geriatric assessment (GA) could significantly change satisfaction all around, according to new research detailed at the American Society of Clinical Oncology (ASCO) meeting by lead study author Supriya Gupta Mohile, Wehrheim professor of medicine at the University of Rochester in New York. Read More

Seeking to 'thread the needle,' TAILORx weaves path through chemo-free breast cancer treatment

CHICAGO – The largest breast cancer adjuvant study ever performed, the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, showed conclusively that the Oncotype DX Breast Recurrence Score (RS) test identified 70 percent of early stage breast cancer patients who receive no benefit from chemotherapy and can be treated effectively with endocrine therapy (ET) alone. Findings also showed that chemotherapy may provide life-saving benefit to the other 30 percent of such patients. Read More

Head-neck undertreated in women vs. men; query HPV, choices by patients

CHICAGO – One of the more eye-opening data rollouts at the American Society of Clinical Oncology (ASCO) involved an analysis of registry data from a California hospital system showing that women with head and neck cancer were, compared to men, less likely to receive intensive chemotherapy (35 percent vs. 46 percent) and radiation (60 percent vs. 70 percent) relative to men. But, controlling for age and other serious medical conditions, a mathematical model demonstrated that the ratio of cancer to noncancer mortality was two times higher for women than the ratio for men. Read More

Regulatory front

A new report by the U.S. Health and Human Services Office of Inspector General (OIG) found that despite a 17 percent decrease in the number of prescriptions for brand drugs under Medicare Part D from 2011 to 2015, total Part D reimbursement for those drugs increased 77 percent.  Read More

Other news to note

Denovo Biopharma LLC, of San Diego, entered a global license agreement with Stanford University School of Medicine. The deal allows Denovo to develop and commercialize DB-102 (enzastaurin), its lead compound, to treat pulmonary arterial hypertension (PAH) and emphysema.  Read More

Financings

Translate Bio Inc., of Lexington, Mass., has filed for an IPO to raise up to $115 million. The company is developing an mRNA therapeutic platform with lead product candidate, MRT-5005, targeting cystic fibrosis, and a phase I/II trial has been initiated. The company plans to list on Nasdaq under the symbol TBIO. Read More

Clinical data for June 4, 2018

Read More

Regulatory actions for June 4, 2018

Read More

Conference data: American Society of Clinical Oncology (Chicago)

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe